Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, Guruprasad P., Thomas, James A., Kaye, Philip V., Lawson, Adam, Ryder, Stephen D., Spendlove, Ian, Austin, Andrew S., Freeman, Jan G. +2 more·2008·Gastroenterology

DOI 10.1053/j.gastro.2008.06.047

Cited by (719)

Items 301–400 of 719

Signal transducer and activator of transcription 5 plays a crucial role in hepatic lipid metabolism through regulation of CD36 expression
Atsushi Hosui, Tomohide Tatsumi, Hayato Hikita, Yoshinobu Saito, Naoki Hiramatsu, Masahiko Tsujii, Lothar G. Hennighausen, Tetsuo Takehara · 2016 · Hepatology Research
Review article: role of glucagon‐like peptide‐1 receptor agonists in non‐alcoholic steatohepatitis, obesity and diabetes—what hepatologists need to know
Alfred Sidney Barritt, Emma Marshman, Mazen Noureddin · 2022 · Alimentary Pharmacology & Therapeutics
Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Daniel Clayton‐Chubb, William W. Kemp, Ammar Majeed, John Samuel Lubel, Alex Hodge, Stuart Keith Roberts · 2023 · Nutrients
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis
Kathleen E. Corey, Mary Eugenia Rinella · 2016 · Digestive Diseases and Sciences
Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview
Asad Izziddin Dajani, A. Abu-Hammour · 2016 · Saudi Journal of Gastroenterology
Linking Cardiovascular Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Role of Cardiometabolic Drugs in MASLD Treatment
Marios Zisis, Maria Eleni Chondrogianni, Θεόδωρος Ανδρουτσάκος, Ilias Rantos, Evangelos K. Oikonomou, Antonios Chatzigeorgiou, Eva N. Kassi · 2025 · Biomolecules
Pioglitazone in the Treatment of Type 2 Diabetes: Safety and Efficacy Review
Cyrus V Desouza, Vijay Shivaswamy · 2010 · Clinical Medicine Insights Endocrinology and Diabetes
Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances
Adnan Said · 2013 · World Journal of Gastroenterology
Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism
McCommis, Kyle S., Finck, Brian N. · 2019 · Cellular and Molecular Gastroenterology and Hepatology
Management of Non-alcoholic Fatty Liver Disease and Steatohepatitis
Thuy‐Anh Le, Rohit Seth Loomba · 2012 · Journal of Clinical and Experimental Hepatology
Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis
Vlad Ratziu, Marwan Ghabril, Manuel Romero‐Gómez, Gianluca Svegliati‐Baroni · 2018 · Transplantation
Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis
James Yarmolinsky, Emmanouil Bouras, Andrei‐Emil Constantinescu, Kimberley Burrows, Caroline J. Bull, Emma E. Vincent, Richard Michael Martin, Olympia Dimopoulou, Sarah Jane Lewis, Victor Rau Moreno et al. · 2023 · Diabetologia
NAFLD: An Emerging Causal Factor for Cardiovascular Disease
Mei Li, Hongmin Wang, Xiao‐Jing Zhang, Jingjing Cai, Hongliang Li · 2023 · Physiology
Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease
Kei Nakajima · 2012 · International Journal of Hepatology
ASB14780, an Orally Active Inhibitor of Group IVA Phospholipase A2, Is a Pharmacotherapeutic Candidate for Nonalcoholic Fatty Liver Disease
Shiho Kanai, Keiichi Ishihara, Eri Kawashita, Toshiyuki Tomoo, Kazuhiro Nagahira, Yasuhiro Hayashi, Satoshi Akiba · 2015 · Journal of Pharmacology and Experimental Therapeutics
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Gebran W. Khneizer, Syed Rizvi, Samer Gawrieh · 2020 · Advances in experimental medicine and biology
Lactoferrin Prevents Hepatic Injury and Fibrosis via the Inhibition of NF-κB Signaling in a Rat Non-Alcoholic Steatohepatitis Model
Yoshinaga Aoyama, Aya Naiki‐Ito, Xiaochen Kuang, Masayuki Komura, Hiroyuki Kato, Yuko Nagayasu, Shingo Inaguma, Hiroyuki Tsuda, Mamoru TOMITA, Yoichi Matsuo et al. · 2021 · Nutrients
Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials
Gu, Yunpeng, Sun, Lei, He, Yining, Yang, Luping, Deng, Chaohua, Zhou, Run, Kong, Tingting, Zhang, Wei, Chen, Yutong, Li, Jie et al. · 2023 · Expert Review of Gastroenterology & Hepatology
Non-alcoholic fatty liver disease resolution following sleeve gastrectomy
Algooneh, Ardeshir, Almazeedi, Sulaiman, Al-Sabah, Salman, Ahmed, Maha, Othman, Feras · 2016 · Surgical Endoscopy
Management of Nonalcoholic Steatohepatitis
Suzanne E. Mahady, Jacob George · 2012 · Clinics in Liver Disease
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
Romina Lomonaco, Janet Chen, Kenneth J. Cusi · 2011 · Therapeutic Advances in Endocrinology and Metabolism
Hypertension exacerbates liver injury and hepatic fibrosis induced by a choline-deficient L-amino acid-defined diet in rats
Shiho Arima, Hirofumi Uto, Rie Ibusuki, Ryo Kumamoto, Shirou Tanoue, Seiichi Mawatari, Kohei Oda, Masatsugu Numata, Hiroshi Fujita, Makoto Oketani et al. · 2013 · International Journal of Molecular Medicine
Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase
Niharika R. Samala, Sarah A. Tersey, Naga Chalasani, Ryan M. Anderson, Raghavendra G. Mirmira · 2017 · Journal of Diabetes and its Complications
Liver Fibrogenesis in Non-Alcoholic Steatohepatitis
Zhaolian Bian, Xiong Ma · 2012 · Frontiers in Physiology
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Nutrition Metabolism and Cardiovascular Diseases
Nonalcoholic Fatty Liver Disease: Identification and Management of High-Risk Patients
Amanda C. Cheung, Carlos Jose Figueredo, Mary Eugenia Rinella · 2019 · The American Journal of Gastroenterology
The Mexican consensus on nonalcoholic fatty liver disease
Raúl Bernal-Reyes, Graciela Castro‐Narro, René Malé-Velázquez, Ramón Carmona-Sánchez, M.S. González-Huezo, Ignacio García-Juárez, Norberto Carlos Chávez-Tapia, C. Aguilar-Salinas, I. Aiza-Haddad, M.A. Ballesteros-Amozurrutia et al. · 2019 · Revista de Gastroenterología de México (English Edition)
Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus
Ralph A. DeFronzo, Rucha J. Mehta, Joel J. Schnure · 2013 · Hospital Practice
Pharmacotherapy for Nonalcoholic Fatty Liver Disease
Samer Gawrieh, Naga Chalasani · 2015 · Seminars in Liver Disease
Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs
Yan Dong Zhao, Wenli Zhao, Hongwu Wang, Ye Zhao, Huaien Bu, Hirokazu Takahashi · 2022 · Medicine
Fatty Liver Disease
DINA G. TINIAKOS, Quentin Mark Anstee, Alastair D. Burt · 2017 · Elsevier eBooks
Proteasome dysfunction under compromised redox metabolism dictates liver injury in NASH through ASK1/PPARγ binodal complementary modules
Debajyoti Das, Avishek Paul, Abhishake Lahiri, Moumita Adak, Sujay Krishna Maity, Ankita Sarkar, Sandip Paul, Partha Chakrabarti · 2021 · Redox Biology
Comprehensive Review of Cardiovascular Disease Risk in Nonalcoholic Fatty Liver Disease
Kevan Josloff, Jacob Beiriger, Adnan Khan, Richard J Gawel, Richard S. Kirby, Aaron D. Kendrick, Abhinav K. Rao, Roy X. Wang, Michelle Schafer, Margaret E. Pearce et al. · 2022 · Journal of Cardiovascular Development and Disease
Nonalcoholic Fatty Liver Disease in Lean/Nonobese and Obese Individuals: A Comprehensive Review on Prevalence, Pathogenesis, Clinical Outcomes, and Treatment
Ankoor H Patel, Dhiraj K. Peddu, Sahil Amin, Mohamed I. Elsaid, Carlos D. Minacapelli, Toni-Marie Chandler, Carolyn Catalano, Vinod K. Rustgi · 2022 · Journal of Clinical and Translational Hepatology
Energy determinants GAPDH and NDPK act as genetic modifiers for hepatocyte inclusion formation
Natasha Tasheva Snider, Sujith V. W. Weerasinghe, Amika Singla, Jessica M. Leonard, Shinichiro Hanada, Philip Andrews, Anna Suk-Fong Lok, M. Bishr Omary · 2011 · The Journal of Cell Biology
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Maria Zachou, Pagona Flevari, Narjes Nasiri Ansari, Constantinos Varytimiadis, Evangelos Kalaitzakis, Eva N. Kassi, Θεόδωρος Ανδρουτσάκος · 2023 · European Journal of Clinical Pharmacology
The association of non-alcoholic fatty liver disease and atrial fibrillation: a review
Aki Juhani Käräjämäki, Janne Hukkanen, Olavi H. Ukkola · 2018 · Annals of Medicine
Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Tiantian Song, Yujiao Jia, Zelin Li, Fei Wang, Luping Ren, Shuchun Chen · 2021 · Diabetes Therapy
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Giulio Marchesini, Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico et al. · 2021 · Digestive and Liver Disease
Hepatic Effects of Rosiglitazone in Rats with the Metabolic Syndrome
Zvi Ackerman, Mor Oron‐Herman, Orit Pappo, Edna Peleg, Rifaat Safadi, Hemda Schmilovitz‐Weiss, Maria Grozovski · 2010 · Basic & Clinical Pharmacology & Toxicology
Non‐alcoholic fatty liver disease (NAFLD): why you should care, when you should worry, what you should do
Edward Lebovics, Jonah N. Rubin · 2011 · Diabetes/Metabolism Research and Reviews
Thiazolidinediones improve hepatic fibrosis in rats with non‐alcoholic steatohepatitis by activating the adenosine monophosphate‐activated protein kinase signalling pathway
Wei Zhang, Rong Wu, Feng Zhang, Yi-Zhi Xu, Bo Liu, Yingying Yang, Huamei Zhou, Lulu Wang, Kaiqiang Wan, Xiaoqiu Xiao et al. · 2012 · Clinical and Experimental Pharmacology and Physiology
The Role of Medications for the Management of Patients with NAFLD
Natalia Mazzella, Laura Maria Ricciardi, Arianna Mazzotti, Giulio Marchesini · 2013 · Clinics in Liver Disease
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Waihong Chung, Kittichai Promrat, Jack R. Wands · 2020 · World Journal of Hepatology
Extracts from Salvia-Nelumbinis naturalis alleviate hepatosteatosis via improving hepatic insulin sensitivity
Li Rita Zhang, Jiaoya Xu, Haiyan Song, Zemin Yao, Guang Ji · 2014 · Journal of Translational Medicine
Focus on Therapeutic Strategies of Nonalcoholic Fatty Liver Disease
Marilena Durazzo, Paola Belci, Alessandro Collo, Enrica Grisoglio, Simona Bo · 2012 · International Journal of Hepatology
Management of fatty liver disease with the metabolic syndrome
Mariana Verdelho Machado, Helena Cortez‐Pinto · 2014 · Expert Review of Gastroenterology & Hepatology
Pterostilbene Improves Hepatic Lipid Accumulation via the MiR-34a/Sirt1/SREBP-1 Pathway in Fructose-Fed Rats
Wen‐Yuan Wu, Xiaoqin Ding, Ting-Ting Gu, Wenjie Guo, Rui‐Qing Jiao, Lin Song, Yang Sun, Ying Pan, Ling‐Dong Kong · 2020 · Journal of Agricultural and Food Chemistry
Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis
Mark Dhinesh Muthiah, Cheng Han Ng, Jieling Xiao, Yip Han Chin, Grace Lim, Wen Hui Lim, Phoebe Wen Lin Tay, Darren Jun Hao Tan, Jie Ning Yong, Xin‐Hui Pan et al. · 2022 · Alimentary Pharmacology & Therapeutics
Pharmacologic Therapy of Non-Alcoholic Steatohepatitis
Vlad Ratziu, Shira Zelber‐Sagi · 2009 · Clinics in Liver Disease
An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug’s effect on cardiovascular disease and non-alcoholic steatohepatitis
Mayer B. Davidson, Deyu Pan · 2017 · Diabetes Research and Clinical Practice
Treatment of Nonalcoholic Steatohepatitis in Adults: Present and Future
Stefano Gitto, Giovanni Vitale, Erica Villa, Pietro Andreoné · 2015 · Gastroenterology Research and Practice
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges
Prarthana Thiagarajan, Guruprasad Padur Aithal · 2019 · Journal of Clinical and Experimental Hepatology
Hypoadiponectinemia and its Association with Liver Fibrosis in Morbidly Obese Patients
Leyla Nazal, Arnoldo J. Riquelme, Nancy Solı́s, Margarita Pizarro, Alex Escalona, Mauricio Burotto, Juan Ignacio Méndez, Catalina Saint-Jean, María José Concha, Stefano Giovanni et al. · 2010 · Obesity Surgery
Full-spectrum antioxidant therapy featuring astaxanthin coupled with lipoprivic strategies and salsalate for management of non-alcoholic fatty liver disease
Mark Frederick McCarty · 2011 · Medical Hypotheses
Clinicopathological features of non‐alcoholic fatty liver disease
Kazushi Sugimoto, Yoshiyuki Takei · 2011 · Hepatology Research
Current management of non-alcoholic fatty liver disease
Quelson Coelho Lisboa, SILVIA MARINHO FEROLLA COSTA, Cláudia Alves Couto · 2016 · Revista da Associação Médica Brasileira
Nonalcoholic Fatty Liver Disease: A Drug Revolution Is Coming
Soung Won Jeong · 2020 · Diabetes & Metabolism Journal
Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Luo, Qian, Wei, Ruojun, Cai, Yuzi, Zhao, Qihan, Liu, Yuning, Liu, Wei Jing · 2022 · Frontiers in Medicine
Current Perspectives on Nonalcoholic Fatty Liver Disease in Women with Polycystic Ovary Syndrome
Wang, Dongxu, He, Bing · 2022 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand
Bunchai Chongmelaxme, Pochamana Phisalprapa, Ratree Sawangjit, Piyameth Dilokthornsakul, Nathorn Chaiyakunapruk · 2018 · PharmacoEconomics
Consensus guidelines for the diagnosis and management of metabolic dysfunction-associated steatotic liver disease in adult Asian Indians with type 2 diabetes
Anoop Misra, Ashish Kumar, Mohammad Shafi Kuchay, Amerta Ghosh, Seema Gulati, Narendra Singh Choudhary, Deep Dutta, Praveen Sharma, Naval K. Vikram, Ashu Rastogi et al. · 2025 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
Clinical Care Pathway for the Risk Stratification and Management of Patients With Metabolic Dysfunction–Associated Steatotic Liver Disease
Fasiha Kanwal, Fernando Bril, Vincent Wai‐Sun Wong, Leon A. Adams, Kim M. Pfotenhauer, NEIL SKOLNIK, Eugene E. Wright, Robert H. Eckel, Mazen Noureddin, Rohit Seth Loomba et al. · 2026 · Gastroenterology
Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease
Vikas Khullar, Angela Dolganiuc, Roberto J. Firpi · 2014 · World Journal of Transplantation
Fibrosis progression rate in a systematic review of placebo‐treated nonalcoholic steatohepatitis
Anna Roskilly, Amy Hicks, Eleanor Taylor, Rebecca L. Jones, Richard Parker, Ian A.C. Rowe · 2020 · Liver International
Current, emerging, and potential therapies for non-alcoholic steatohepatitis
Zhen Lu Yang, Lin Wang · 2023 · Frontiers in Pharmacology
Compound K modulates fatty acid‐induced lipid droplet formation and expression of proteins involved in lipid metabolism in hepatocytes
Moon-Sun Kim, Kyoungtae Lee, Tristan J. Iseli, Andrew J. Hoy, Jacob George, Thomas Grewal, Basil D. Roufogalis · 2013 · Liver International
Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin
Mingyan Zhou, Aimin Xu, Karen S.L. Lam, Paul Kwong Hang Tam, Chi‐Ming Che, Lawrence Chan, In‐Kyu Lee, Donghai Wu, Yu Wang · 2010 · Journal of Hepatology
Hepatic Steatosis and Steatohepatitis: Are they Really Two Distinct Entities?
Cory M. Fielding, Paul Angulo · 2014 · Current Hepatology Reports
SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Naser Eddin Gharaibeh, Marie-Noel Rahhal, Leili Rahimi, Faramarz Ismail‐Beigi · 2019 · Diabetes Metabolic Syndrome and Obesity
Fatty liver disease
Elizabeth M. Brunt, Brent A. Neuschwander‐Tetri, Alastair D. Burt · 2011 · Elsevier eBooks
Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment
Mingming Chen, Jingjing Cai, Yao Yu, Zhi‐Gang She, Hongliang Li · 2019 · Gene Expression
Management of nonalcoholic fatty liver disease in the Middle East
Faisal M. Sanai, Faisal Abdulrahman Abaalkhail, Fuad A. Hasan, Muhammad H. Farooqi, Nawal Alnahdi, Zobair M. Younossi · 2020 · World Journal of Gastroenterology
Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD)
Ignazio Grattagliano, Agostino Di Ciaula, Jacek Baj, Emilio Molina‐Molina, Harshitha Shanmugam, Gabriella Garruti, David Q.‐H. Wang, Piero Portincasa · 2021 · Methods in molecular biology
Burning hepatic fat: Therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease # †
Marco A. Arrese · 2008 · Hepatology
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Da Zhou, Jian‐Gao Fan · 2024 · Chinese Medical Journal
State of the art
Michelle Y. Pearlman, Rohit Seth Loomba · 2014 · Current Opinion in Gastroenterology
Pioglitazone and mechanisms of CV protection
Erland Erdmann, Robert G. Wilcox · 2009 · QJM
Advantages and Disadvantages of Hyperbaric Oxygen Treatment in Mice with Obesity Hyperlipidemia and Steatohepatitis
Koichi Tsuneyama, Yen‐Chen Chen, Makoto Fujimoto, Yoshiyuki Sasaki, Wataru Suzuki, Tsutomu Shimada, Seiichi Iizuka, Mitsunobu Nagata, Masaki Aburada, Shao‐Yuan Chen · 2011 · The Scientific World JOURNAL
The impact of steatosis on liver regeneration
Manon Allaire, Hélène Gilgenkrantz · 2018 · Hormone Molecular Biology and Clinical Investigation
Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system
Parijat Pandey, Dinesh Kumar Chellappan, Murtaza M. Tambuwala, Hamid A. Bakshi, Kamal Dua, Harish Dureja · 2019 · International Journal of Biological Macromolecules
Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease
Emily E. Brown, Theresa Hydes, A. Hamid, Daniel James Cuthbertson · 2021 · Clinical Therapeutics
The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
Andrew Kamsoko Ndakotsu, Govinathan Vivekanandan · 2022 · Cureus
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials
Jihyun An, Joo Hyun Sohn · 2022 · Clinical and Molecular Hepatology
Nonalcoholic fatty liver disease from a primary care perspective
Jeanne M. Clark, Donna R. H. Cryer, Michelle Morton, Jay H. Shubrook · 2023 · Diabetes Obesity and Metabolism
Overview and prospect of NAFLD: Significant roles of nutrients and dietary patterns in its progression or prevention
Tianyu Mao, Yiwen Sun, Xinyi Xu, Kang He · 2023 · Hepatology Communications
Treatment of nonalcoholic steatohepatitis with colestimide
Makiko Taniai, Etsuko Hashimoto, Maki Tobari, Satoru Yatsuji, Ikuko Haruta, Katsutoshi Tokushige, Keiko Shiratori · 2009 · Hepatology Research
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
Thaninee Prasoppokakorn, Panyavee Pitisuttithum, Sombat Treeprasertsuk · 2021 · Journal of Clinical and Translational Hepatology
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Robert Gareth Gish, Jian‐Gao Fan, Zahra Dossaji, Jeanne Fichez, Tooba Laeeq, Magnus J. Chun, Jérôme Boursier · 2024 · Hepatology International
Prevention and treatment of nonalcoholic fatty liver disease
Giovanni Targher, Alessandro Bellis, Paolo Fornengo, Maria Francesca Ciaravella, Isabella Pichiri, Paolo Cavallo Perin, Bruno Trimarco, Giulio Marchesini · 2010 · Digestive and Liver Disease
Nonalcoholic Fatty Liver Disease
Samer Gawrieh · 2016 · Springer eBooks
Beneficial and Paradoxical Roles of Anti-Oxidative Nutritional Support for Non-Alcoholic Fatty Liver Disease
Daisuke Uchida, Akinobu Takaki, Takuya Adachi, Hiroyuki Okada · 2018 · Nutrients
Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
Krzysztof Tomasiewicz, Robert Flisiak, Waldemar Halota, Jerzy Jaroszewicz, Dariusz Marek Lebensztejn, Wojciech Lisik, Piotr Małkowski, Małgorzata Pawłowska, Anna Piekarska, Krzysztof Adam Simon et al. · 2018 · Clinical and Experimental Hepatology
Liver‐related long‐term outcomes of thiazolidinedione use in persons with type 2 diabetes
Fu‐Shun Yen, Yu‐Cih Yang, Chii‐Min Hwu, James Cheng‐Chung Wei, Yi‐Hsiang Huang, Ming‐Chih Hou, Chih‐Cheng Hsu · 2020 · Liver International
Review: Advances in the treatment of nonalcoholic fatty liver disease
Sanjeev R. Mehta · 2010 · Therapeutic Advances in Endocrinology and Metabolism
Exploring Varied Treatment Strategies for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Amani Elshaer, David M. H. Chascsa, Blanca Lizaola‐Mayo · 2024 · Life
American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes – 2026 Update
Susan Leanne Samson, Priyathama Vellanki, Lawrence Blonde, Irl B. Hirsch, Thanh D. Hoang, Scott D. Isaacs, Kenneth E. Izuora, Cecilia C. Low Wang, Cheow Peng Ooi, Blanca Iris Padilla et al. · 2026 · Endocrine Practice
Republished: Non-alcoholic fatty liver disease: a practical approach to treatment
Jessica Katharine Dyson, Quentin Mark Anstee, Stuart McPherson · 2015 · Postgraduate Medical Journal
Nonalcoholic Fatty Liver Disease
Jae Sung Ko · 2010 · Korean Journal of Gastroenterology
Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis
Kannan Sridharan, Gowri Sivaramakrishnan, Reginald Paul Sequeira, Abdelaziz Elamin · 2018 · Postgraduate Medical Journal